Trial Profile

Vascepa to Accelerate Lipoprotein Uptake and Elimination (VALUE): An Open-Label, Mechanistic, Randomized, Controlled, Single-Center Trial of AMR101 in Patients With Dyslipidemia

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ethyl eicosapentaenoic acid (Primary)
Indications Dyslipidaemias; Hypertriglyceridaemia; Lipid metabolism disorders
Focus Pharmacodynamics
Acronyms VALUE

15 Oct 2021 Status changed from active, no longer recruiting to completed.
14 Dec 2020 According to an Amarin Corporation media release, the company will host an audio webcast on December 14, 2020 to further discuss VASCEPA-related findings presented during the NLA Scientific Sessions 2020.
14 Dec 2020 According to an HLS Therapeutics media release, data from this study was presented at the National Lipid Association (NLA) Scientific Sessions 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com